{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:46:50Z","timestamp":1789879610245,"version":"4.0.1"},"reference-count":44,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,24]]},"DOI":"10.14797\/mdcvj.293","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T11:52:33Z","timestamp":1632484353000},"page":"36-47","source":"Crossref","is-referenced-by-count":36,"title":["Aspirin in the Modern Era of Cardiovascular Disease Prevention"],"prefix":"10.14797","volume":"17","author":[{"given":"Ella","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6414-9803","authenticated-orcid":false,"given":"James M. G.","family":"Curneen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-5479","authenticated-orcid":false,"given":"John W.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"issue":"7","key":"key20210924072521_B1","first-page":"768","article-title":"Aspirin: a historical and contemporary therapeutic overview","volume":"123","year":"2011"},{"key":"key20210924072521_B2","first-page":"352","volume-title":"Aspirin: The Remarkable Story of a Wonder Drug","year":"2004"},{"issue":"6921","key":"key20210924072521_B3","first-page":"81","article-title":"Antiplatelet Trialists\u2019 Collaboration","volume":"308","author":"Collaborative overview of randomised trials of antiplatelet therapy\u2014I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","year":"1994","journal-title":"BMJ"},{"issue":"9678","key":"key20210924072521_B4","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Antithrombotic Trialists\u2019 (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"Lancet"},{"issue":"16","key":"key20210924072521_B5","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.120.045695","article-title":"Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or Is Reappraisal Warranted?","volume":"142","year":"2020","journal-title":"Circulation"},{"issue":"6618","key":"key20210924072521_B6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/bmj.296.6618.320","article-title":"Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists\u2019 Collaboration","volume":"296","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"7329","key":"key20210924072521_B7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"9038","key":"key20210924072521_B8","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"issue":"4","key":"key20210924072521_B9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/eurheartj\/ehaa824","article-title":"Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"key20210924072521_B10","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention","volume":"66","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"key20210924072521_B11","first-page":"2251","article-title":"Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD","volume":"13","year":"2020","journal-title":"JACC: Cardiovascular Interventions"},{"issue":"3","key":"key20210924072521_B12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"key20210924072521_B13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"key20210924072521_B14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y 12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis","volume":"142","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"key20210924072521_B15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"key20210924072521_B16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"10186","key":"key20210924072521_B17","first-page":"2155","article-title":"The rise and fall of aspirin in the primary prevention of cardiovascular disease","volume":"393","year":"2019"},{"issue":"10","key":"key20210924072521_B18","first-page":"e123","article-title":"2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","year":"2016","journal-title":"Circulation"},{"issue":"6618","key":"key20210924072521_B19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"3","key":"key20210924072521_B20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study","volume":"321","author":"Steering Committee of the Physicians\u2019 Health Study Research Group","year":"1989","journal-title":"N Engl J Med"},{"issue":"9098","key":"key20210924072521_B21","first-page":"233","article-title":"The Medical Research Council\u2019s General Practice Research Framework","volume":"351","author":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","year":"1998","journal-title":"Lancet"},{"issue":"9118","key":"key20210924072521_B22","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","year":"1998","journal-title":"Lancet"},{"issue":"9250","key":"key20210924072521_B23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project","volume":"357","author":"Collaborative Group of the Primary Prevention Project","year":"2001","journal-title":"Lancet"},{"issue":"13","key":"key20210924072521_B24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"key20210924072521_B25","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","year":"2008","journal-title":"BMJ"},{"issue":"18","key":"key20210924072521_B26","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","year":"2008","journal-title":"JAMA"},{"issue":"9","key":"key20210924072521_B27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","year":"2010","journal-title":"JAMA"},{"issue":"23","key":"key20210924072521_B28","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1001\/jama.2014.15690","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial","volume":"312","year":"2014","journal-title":"JAMA"},{"issue":"12","key":"key20210924072521_B29","first-page":"804","article-title":"Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S","volume":"164","year":"2016","journal-title":"Preventive Services Task Force"},{"issue":"8","key":"key20210924072521_B30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamainternmed.2016.2648","article-title":"Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment","volume":"176","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"10152","key":"key20210924072521_B31","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"key20210924072521_B32","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"key20210924072521_B33","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"ASPREE Investigator Group. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"key20210924072521_B34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"International Polycap Study 3 Investigators. Polypill with or without Aspirin in Persons without Cardiovascular Disease","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"key20210924072521_B35","doi-asserted-by":"crossref","first-page":"glaa316","DOI":"10.1093\/gerona\/glaa316","article-title":"ASPREE Investigator Group. Effect of Aspirin on Activities of Daily Living Disability in Community-Dwelling Older Adults","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"11","key":"key20210924072521_B36","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","year":"2019","journal-title":"Circulation"},{"issue":"16","key":"key20210924072521_B37","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMe1812000","article-title":"Should Aspirin Be Used for Primary Prevention in the Post-Statin Era?","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"key20210924072521_B38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjcard.2020.11.014","article-title":"Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence","volume":"141","year":"2021","journal-title":"Am J Cardiol"},{"issue":"20","key":"key20210924072521_B39","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMclde1903004","article-title":"\u201cDoctor, Should I Keep Taking an Aspirin a Day?\u201d","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"key20210924072521_B40","first-page":"e1162","article-title":"Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology","volume":"139","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"key20210924072521_B41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.7326\/M14-1281","article-title":"An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort","volume":"162","year":"2015","journal-title":"Ann Intern Med"},{"issue":"25","key":"key20210924072521_B42","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","year":"2019","journal-title":"Circulation"},{"issue":"19","key":"key20210924072521_B43","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.119.045010","article-title":"Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis)","volume":"141","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"key20210924072521_B44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamacardio.2020.4939","article-title":"Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease","volume":"6","year":"2021","journal-title":"JAMA Cardiol"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T11:54:25Z","timestamp":1632484465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.293\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,9,24]]}},"alternative-id":["10.14797\/mdcvj.293"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.293","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}